Benefits and Risks Associated With Continuation of Anti-Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease : A Nationwide Emulation Trial.
Antoine MeyerAnke NeumannJérôme DrouinAlain WeillFranck CarbonnelRosemary Dray-SpiraPublished in: Annals of internal medicine (2022)
None.